Pfizer Venture Investments

About The Fund

Pfizer Venture Investments is the venture capital arm of Pfizer, established in 2004 with headquarters in New York, New York, United States. They specialize in investing in companies operating in a diverse array of sectors, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT and other technologies. The firm is heavily focused on growth-stage investments, fund investing, spinout opportunities, and PIPEs (Private Investment in Public Equity). Their investment strategy is primarily directed towards areas of strategic interest to Pfizer, looking to remain at the forefront of life science advances and contribute to Pfizer’s broader mission of advancing healthcare innovation. With a structured approach to venture capital investment, Pfizer Venture Investments aims to identify and invest in emerging companies that are developing transformative medicines and technologies, potentially enhancing Pfizer’s pipeline and shaping the future of the industry. They actively support their portfolio companies throughout their growth cycles by providing strategic guidance as well as access to capital and Pfizer's extensive expertise. Their total assets under management are around $1.6 billion, with a current capital commitment of $900 million from Pfizer. They can lead or join a syndicate of investors and will seek board representation proportionate to their investment. Their investment focus is primarily on therapeutics, allocating roughly 80% to this area, while also considering platform technologies, diagnostics, drug delivery, pharmaceutical services, and technologies that have the potential to transform drug discovery and development. Geographically, they are primarily focused on the U.S. but may invest up to 20 percent internationally. They are able to invest in private companies across all developmental stages, with an emphasis on early-stage opportunities, offering up to $20 million in the first investment and reserving an allocation for follow-on investments. Pfizer Venture Investments has the flexibility to engage in potential business relationships with their investees, evaluated as part of the investment criteria, which might result in collaborations parallel to the investments or explored in the future. Their specialty includes engaging in Series A, Series B, Pre-seed, and Seed funding rounds. The firm's minimal investment is $100,000, with a maximum of $15 million, and a sweet spot of around $10 million per investment.